Aprea dis­clos­es sec­ond clin­i­cal hold in a week, this time for lym­phoma study

Bare­ly a week af­ter Aprea got hit with a clin­i­cal hold on a slate of myeloid ma­lig­nan­cy tri­als, the biotech re­vealed its lym­phoid ma­lig­nan­cy pro­gram is al­so be­ing halt­ed.

In con­trast to the pre­vi­ous dis­clo­sure, where the com­pa­ny didn’t spec­i­fy a rea­son for the par­tial hold, Aprea said the FDA had con­cerns about its lym­phoid ma­lig­nan­cy study af­ter re­view­ing safe­ty and ef­fi­ca­cy da­ta from the Phase III MDS clin­i­cal tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER